

## Mild Cognitive Impairment Market by Companies Involved in Therapeutics Development and Assessment 2018-2024

PUNE, INDIA, March 22, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Mild Cognitive Impairment - Pipeline Review, H1 2018"

Mild Cognitive Impairment

Overview

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Click here for sample report @ <a href="https://www.wiseguyreports.com/sample-request/3066541-mild-cognitive-impairment-pipeline-review-h1-2018">https://www.wiseguyreports.com/sample-request/3066541-mild-cognitive-impairment-pipeline-review-h1-2018</a>

Major Key Players:

Avraham Pharmaceuticals Ltd

Biogen Inc

CereSpir Inc

Eisai Co Ltd

Eli Lilly and Co

Genzyme Corp

IntelGenx Corp

Mild Cognitive Impairment Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 10, 6, 1 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Mild Cognitive Impairment - Competitive Analysis

Key players are making innovative developments in Mild Cognitive Impairment industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment.

The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Mild Cognitive Impairment therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Mild Cognitive Impairment therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment.

## .Continued

For Detailed Reading Please visit @ <a href="https://www.wiseguyreports.com/reports/3066541-mild-cognitive-impairment-pipeline-review-h1-2018">https://www.wiseguyreports.com/reports/3066541-mild-cognitive-impairment-pipeline-review-h1-2018</a>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

**NORAH TRENT** 

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wisequyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent WiseGuy Research Consultants Pvt. Ltd. +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.